80 related articles for article (PubMed ID: 16636293)
1. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.
Ishihara A; Kanatani A; Mashiko S; Tanaka T; Hidaka M; Gomori A; Iwaasa H; Murai N; Egashira S; Murai T; Mitobe Y; Matsushita H; Okamoto O; Sato N; Jitsuoka M; Fukuroda T; Ohe T; Guan X; MacNeil DJ; Van der Ploeg LH; Nishikibe M; Ishii Y; Ihara M; Fukami T
Proc Natl Acad Sci U S A; 2006 May; 103(18):7154-8. PubMed ID: 16636293
[TBL] [Abstract][Full Text] [Related]
2. Adipose Y5R mRNA is higher in obese than non-obese humans and is correlated with obesity parameters.
Chatree S; Sitticharoon C; Maikaew P; Uawithya P; Chearskul S
Exp Biol Med (Maywood); 2018 May; 243(9):786-795. PubMed ID: 29763369
[TBL] [Abstract][Full Text] [Related]
3. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice.
Kushi A; Sasai H; Koizumi H; Takeda N; Yokoyama M; Nakamura M
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15659-64. PubMed ID: 9861026
[TBL] [Abstract][Full Text] [Related]
4. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY
Kloock S; Haerting N; Herzog G; Oertel M; Geiger N; Geier A; Sequeira V; Nickel A; Kohlhaas M; Fassnacht M; Dischinger U
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542814
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread.
Sigorski D; Wesołowski W; Gruszecka A; Gulczyński J; Zieliński P; Misiukiewicz S; Kitlińska J; Iżycka-Świeszewska E
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5803-5822. PubMed ID: 36583743
[TBL] [Abstract][Full Text] [Related]
6. Protection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4R.
Lund C; Ranea-Robles P; Falk S; Rausch DM; Skovbjerg G; Vibe-Petersen VK; Krauth N; Skytte JL; Vana V; Roostalu U; Pers TH; Lund J; Clemmensen C
Nat Commun; 2024 Feb; 15(1):1192. PubMed ID: 38331907
[TBL] [Abstract][Full Text] [Related]
7. The Role of Neuropeptide Y in Adipocyte-Macrophage Crosstalk during High Fat Diet-Induced Adipose Inflammation and Liver Steatosis.
Park S; Komatsu T; Hayashi H; Mori R; Shimokawa I
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829968
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y resists excess loss of fat by lipolysis in calorie-restricted mice: a trait potential for the life-extending effect of calorie restriction.
Park S; Komatsu T; Kim SE; Tanaka K; Hayashi H; Mori R; Shimokawa I
Aging Cell; 2017 Apr; 16(2):339-348. PubMed ID: 28101970
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the understanding of how neuropeptide Y and
Shipp SL; Cline MA; Gilbert ER
Adipocyte; 2016; 5(4):333-350. PubMed ID: 27994947
[TBL] [Abstract][Full Text] [Related]
10. Green tea reduces body fat via upregulation of neprilysin.
Muenzner M; Tappenbeck N; Gembardt F; Rülke R; Furkert J; Melzig MF; Siems WE; Brockmann GA; Walther T
Int J Obes (Lond); 2016 Dec; 40(12):1850-1855. PubMed ID: 27698343
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 Receptor.
Long M; Zhou J; Li D; Zheng L; Xu Z; Zhou S
PLoS One; 2015; 10(5):e0126714. PubMed ID: 25993471
[TBL] [Abstract][Full Text] [Related]
12. The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression.
Hsieh YS; Kuo MH; Chen PN; Kuo DY
Neuromolecular Med; 2013 Mar; 15(1):159-68. PubMed ID: 23179670
[TBL] [Abstract][Full Text] [Related]
13. Chemistry and biology of multicomponent reactions.
Dömling A; Wang W; Wang K
Chem Rev; 2012 Jun; 112(6):3083-135. PubMed ID: 22435608
[No Abstract] [Full Text] [Related]
14. Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice.
Sørensen G; Jensen M; Weikop P; Dencker D; Christiansen SH; Loland CJ; Bengtsen CH; Petersen JH; Fink-Jensen A; Wörtwein G; Woldbye DP
Psychopharmacology (Berl); 2012 Aug; 222(4):565-77. PubMed ID: 22367168
[TBL] [Abstract][Full Text] [Related]
15. A role for neuropeptide Y Y5 but not the Y1-receptor subtype in food deprivation-induced reinstatement of heroin seeking in the rat.
Maric T; Sedki F; Chafetz D; Schoela N; Shalev U
Psychopharmacology (Berl); 2011 Dec; 218(4):693-701. PubMed ID: 21629996
[TBL] [Abstract][Full Text] [Related]
16. NPY receptors as potential targets for anti-obesity drug development.
Yulyaningsih E; Zhang L; Herzog H; Sainsbury A
Br J Pharmacol; 2011 Jul; 163(6):1170-202. PubMed ID: 21545413
[TBL] [Abstract][Full Text] [Related]
17. Recent updates on the melanin-concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists.
Chung S; Parks GS; Lee C; Civelli O
J Mol Neurosci; 2011 Jan; 43(1):115-21. PubMed ID: 20582487
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.
Stafford JM; Yu F; Printz R; Hasty AH; Swift LL; Niswender KD
Diabetes; 2008 Jun; 57(6):1482-90. PubMed ID: 18332095
[TBL] [Abstract][Full Text] [Related]
19. Distribution of peripherally injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: enrichment in the area postrema.
Dumont Y; Moyse E; Fournier A; Quirion R
J Mol Neurosci; 2007; 33(3):294-304. PubMed ID: 17952639
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.
Yoshimoto R; Miyamoto Y; Shimamura K; Ishihara A; Takahashi K; Kotani H; Chen AS; Chen HY; Macneil DJ; Kanatani A; Tokita S
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13866-71. PubMed ID: 16954192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
